Abstract. The organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1) plays an important role in the transport of endogenous and xenobiotic compounds, such as bile acids and rifampin. In this study, the association between OATP1B1 polymorphisms and rifampin hepatotoxicity was investigated using integrated population genetic analysis and functional studies. A total of 273 unrelated patients treated with rifampin were recruited. The allele frequencies were examined in patients with drug (rifampin)-induced liver injury (DILI) (n=118) and without (non-DILI) (n=155). Functional analyses were conducted to determine whether the inhibition of bile acids by rifampin was associated with OATP1B1 variants. In the present study, 24 single nucleotide polymorphisms (SNPs) in OATP1B1 were detected in a Chinese population, with two of them causing an amino acid change (rs2306283 and rs4149056). The haplotypes constructed by these two SNPs were OATP1B1 
Introduction
Rifampin (RMP) is one of the major antituberculosis drugs, a second-choice antistaphylococcal agent and an effective medicine in controlling pruritus in primary biliary cirrhosis (1) (2) (3) . The common adverse reactions to RMP include fever, nausea, vomiting, diarrhea, abdominal pain, hemolytic anemia, thrombocytopenia, liver injury and tubular defects. The hepatotoxicity induced by RMP was first reported in 1971, and it has an incidence rate of 5 to 12.5% (4, 5) . RMP-induced hepatotoxicity can be divided into three categories: hepatocellular, cholestatic or mixed-type injury (6) . In spite of the well-accepted toxicity of RMP in vivo, its toxic mechanism remains unclear. Recently, one important mechanism was determined to be a rise in serum bilirubin via competitive inhibition of hepatocyte bilirubin transport by RMP (7) . The inhibition of the hepatic uptake of bile acid has been proposed as the mechanism responsible for RMP-induced cholestasis (8) . Notably, the genetic polymorphisms of bile acid transporters have been reported to be closely related to the susceptibility to RMP hepatotoxicity (9) .
Organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1) is one of the most important bile acid transporters. It is mainly expressed on the basolateral membrane of human hepatocytes and is responsible for bilirubin uptake (10, 11) . Several studies have demonstrated that OATP1B1 plays an important role in the hepatic uptake of RMP (12) . In particular, it has displayed a great capability for RMP transport in HeLa cells, with RMP uptake being markedly decreased by the OATP1B1 allelic variants (13) . To date, however, many studies of RMP hepatotoxicity have concentrated on the transporters that export RMP, and few studies have been published concerning the importance of the transporters that uptake RMP. In fact, RMP inhibits the uptake of bile acids by OATP1B1 (14) . For example, RMP inhibits OATP1B1-mediated substrate uptake into the liver in a Xenopus laevis oocyte expression system (13 uptake of bilirubin and RMP, thus directly leading to changes in the susceptibility to RMP hepatotoxicity (15) . The association between functional single nucleotide polymorphisms (SNPs) in the OATP1B1 gene and RMP-induced liver injury in a Chinese population, remains, however, unclear.
The naturally occurring sequence variations in the SLCO1B1 gene leads to genetic differences that affect susceptibility to RMP hepatotoxicity. Thus, in the present study, SNPs in SLCO1B1 were systemically screened, and the association of the SLCO1B1 polymorphisms with susceptibility to RMP-induced liver injury in a Chinese population was investigated. Then, cells expressing the variants of OATP1B1 were used as an in vitro model to assess the inhibitory effects of RMP on bile acid transport.
Materials and methods
Participants. A total of 273 unrelated patients treated with RMP were recruited in this study. All of the participants lived in Chongqing, China. The patients were admitted to the Institute of Digestive Disease and Infectious Disease of the Southwest Hospital and the Chongqing Antituberculosis Clinic between January 1, 2009 and January 1, 2011. They were enrolled in the study if they met the following criteria: i) were 18-65 years of age, and ii) had RMP treatment prescribed for >3 months. Patients were not eligible if they had pre-existing cardiovascular, renal, hepatic, hematologic or immunologic diseases. Drug-induced liver injury (DILI) was defined as serum alanine aminotransferase (ALT) levels three or more times the upper limit of normal (ULN), and/or serum bilirubin levels two or more times the ULN. Patients diagnosed with DILI had liver injury occurring after RMP retreatment and had previously normal serum ALT levels. The type of liver damage was classified according to the International Consensus Meeting Criteria (16, 17) using ALT and alkaline phosphatase activity, expressed as a multiple of the upper limit of normality, to determine the ratio (R) of ALT/AP. The type of liver damage was defined as hepatocellular when R≥5, cholestatic when R≤2 and mixed when 2<R<5. The protocol for this study was approved by the Ethics Committee of the Southwest Hospital, Chongqing, China. Informed consent was obtained from the patients, and patient confidentiality was preserved according to the guidelines for studies of human subjects.
Discovery of SNPs and determination of haplotypes. SNP screening of the ~9.1-kb region of SLCO1B1 (NT_009714 http://www.ncbi.nlm.nih.gov/gene/10599) continuously from the 5' flanking to 3' flanking genomic regions (including all exons, relevant exon-intron boundaries and 600 bp of the promoter region) was performed by polymerase chain reaction (PCR) direct sequencing. SNP candidates were identified by the PolyPhred program and inspected by two observers. SNP positions and individual genotypes were confirmed by reamplifying and resequencing the SNP site from the opposite strand. The screening panel included 32 unrelated individuals randomly selected from the RMP-induced liver injury group. The sample size provided a 95% probability of detecting haplotypes with a minimum frequency of 5.4% (18) . The pairwise linkage disequilibrium (LD) measures were calculated using the Arlequin package (University of Geneva, Geneva, Switzerland), and the value of r 2 was plotted using the LDA program.
SLCO1B1 genotyping. Genomic DNA was extracted from peripheral blood leukocytes using 2 ml of whole blood and the EZNA blood DNA kit (Omega Bio-Tek). The participants in the study were genotyped for the 388A>G (N130D, rs2306283) and 521T>C (V174A, rs4149056) SNPs in the SLCO1B1 gene by allelic discrimination with TaqMan ® using Minor Groove Binder (MGB) DNA oligonucleotide technology. Genotyping for the 388A>G and 521T>C SNPs was performed with validated 6-carboxyfluorescein (FAM) or VIC dye-labeled MGB-TaqMan Genotyping Assays (Applied Biosystems, Foster City, CA, USA). The accuracy of the SNP genotyping data was validated by direct sequencing of 8% masked, random samples of patients. and selected with 1,200 µg/ml zeocin (Gibco, Grand Island, NY, USA). Those colonies stably expressing OATP1B1 were cultured in 10% fetal bovine serum with zeocin (800 µg/ ml). The pcDNA3.1-GFP vector alone was used to obtain background activity (mock). The expression of the OATP1B1 variants was verified by reverse transcriptase (RT)-PCR and double-fluorescence confocal microscopy using the protocol described by Kameyama et al (19) . Transport studies of RMP and ( 3 H)taurocholic acid (TCA) were carried out as previously described (14, 20) . HEK293 cells stably expressing OATP1B1 were grown on poly-D-lysine-coated 12-well culture plates. The expression of OATP1B1 was induced by 10 mM sodium butyrate for 24 h. The HEK293 cells with the highest transport activities were used in the functional analysis. Then, experiments were initiated by gently removing medium and adding 200 µl transport medium (118 mM NaCl, 23.8 mM NaHCO 3 , 4.83 mM KCl, 0.96 mM KH 2 PO 4 , 1.20 mM MgSO 4 , 12.5 mM HEPES, 5 mM glucose and 1.53 mM CaCl 2 adjusted to pH 7.4) containing radiolabeled drug ( 3 H)TCA (1 µM) (PerkinElmer Life Sciences, Boston, MA, USA) for 10 min. RMP (Sigma, USA) was first dissolved in dimethylsulfoxide (DMSO; 100%) and subsequently diluted 1:100 in the incubation medium. Transport for RMP was determined after 30 min of incubation with 0, 10, 20, 50, 75 and 100 µM at 37˚C. At the end of the experiment, cells were washed with ice-cold PBS three times and lysed with 350 µl of 0.1 N NaOH. Then, 10 µl aliquots of cell lysate were used to determine protein concentration by the bicinchoninic acid (BCA) assay method. Retained cellular radioactivity was quantified by liquid scintillation spectrometry (Beckman LS 6500 Multi-Purpose Scintillation Counter). The OATP1B1-mediated uptake was calculated after subtracting the uptake by the background from the uptake by OATP1B1 variant-transfected cells at each concentration.
Construction
Statistical analysis. Statistical analysis was performed using SPSS software (Version 11.5; SPSS Inc., Chicago, IL, USA). Genotype and haplotype frequencies were determined by gene counting, and the significance of deviations from Hardy-Weinberg equilibrium was tested using the random permutation procedure implemented in the Arlequin package. The association between genotyped polymorphisms and disease risk was estimated with an unconditional logistic regression analysis and represented as p-values, odds ratios (ORs) and 95% confidence intervals (95% CIs). To estimate the kinetic parameters for the uptake of ( 3 H)TCA by the HEK293-OATP1B1-overexpressing cell system, ( 3 H)TCA uptake rates were calculated by subtracting the transport rate of background cells from that of OATP1B1-expressing cells. The transport kinetics data were analyzed with the Prism software (GraphPad Software, Inc., La Jolla, CA, USA). The kinetic parameter was defined as pmol x mg protein -1 x min -1 . p<0.05 was considered a significant difference for all statistical analyses.
Results

Sequence variations in the SLCO1B1 genomic region.
Sequencing of the 9,126-bp SLCO1B1 genomic regions in the 32 samples revealed 24 SNPs (Table I) . Of these variations, 4 were located in coding exons (2 synonymous and 2 nonsynonymous), 14 in introns and 4 in the 3' untranslated region. This study focused on the non-synonymous variants, snp6 (388A>G, rs2306283) and snp11 (521T>C, rs4149056), as they resulted in amino acid changes. Analysis of the genotyping data generated by HapMap revealed that SLCO1B1 had three haplotype blocks. Snp6 and snp11 were in the third block and had low paired LD (r 2 =0.036).
Case-control study. During 2009-2011, 273 patients were enrolled in this study, of whom 118 fulfilled the DILI criteria. There were no significant differences between DILI and non-DILI group populations in terms of age (mean 40.5 vs. 39.3 years) and gender ratio (female 51.7 vs. 45.1%). The DILI patients were classified into two subgroups according to the International Consensus Meeting Criteria: 58 patients with hepatocellular injury (HC group) and 60 patients with cholestatic/mixed injury (CS/mixed group). There were no significant differences between the two groups in terms of age, gender, drinking history and smoking status (Table II) . All of the recruited patients were successfully genotyped for the 388A>G (rs2306283) and 521T>C (rs4149056) SNPs. The genotype distributions of the 388A>G and 521T>C frequencies in the HC, CS/mixed and non-DILI groups are given in Table III . The genotype distributions of these two SNPs (388A>G, 521T>C) were in Hardy-Weinberg equilibrium in each group (for non-DILI group, p=0.1012, 0.6367; for HC group, p=0.4121, 0.2958; for CS/mixed group, p=0.1650, 0.3806). The univariate analysis of the factors analyzed and their association with the risk of DILI are also given in Table III . The frequency of the 388A>G polymorphism was not significantly different between the non-DILI group and the other two groups (p=0.5562, 0.5136). For the 521T>C polymorphism, however, there was a significant difference in the haplotype frequencies between the DILI and non-DILI patients. For this SNP, the frequency of the C allele was 0.1833 in the HC group, 0.1207 in the CS/mixed group and 0.0645 in the non-DILI group. Subjects bearing the 521C allele had an increased susceptibility to RMP-induced liver injury compared to those with the 521T allele (p=0.0233).
Next, the frequencies of the SLCO1B1 haplotypes containing the 388A>G and 521T>C SNPs (Table IV) were analyzed to determine which haplotype specifically correlated with RMP-induced liver injury. Four haplotypes were observed, with the * 5 (388A521C) haplotype having a frequency <5%. (Fig. 1A) . The levels of stably expressed OATP1B1 mRNA in the HEK293 cells were analyzed by RT-PCR. The mRNA levels were apparently equal among the four OATP1B1 variants (Fig. 2B) . The cellular locations of each of the OATP1B1 variants were then investigated by immunocytochemical staining. Double-fluorescence and confocal microscopy revealed that GFP-fused OATP1B1 was expressed at the peripheral plasma membrane of the HEK cells (Fig. 1C) .
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Functional analysis of the OATP1B1 variants in vitro.
The calculation of the uptake of TCA (1 µM) is shown in Fig. 2A . The ( 3 H)TCA uptake activity of the OATP1B1 * 1a and other variants differed. There was a significant difference between the HEK293 cells stably expressing the OATP1B1 variants and the mock cells; the uptake of ( 3 H)TCA into the HEK293-OATP variant cells was 6-10 times higher than that into the mock cells. In 10 min, the uptake of ( , respectively. The uptake of bile acid was reduced in the presence of the * 5 and * 15 haplotypes (both containing the 521C allele) compared to the * 1b haplotype (16.9-42.8%). Next, the inhibitory effect of RMP on the uptake of ( 3 H)TCA was examined ( Fig. 2B-E) . The OATP1B1-mediated uptake of ( The two SNPs, 388A>G (Asn130Asp) and 521T>C (Val174Ala), are located within the SLCO1B1 gene exons, and their associated amino acids are found at the outer loop between TM3 and TM4 of OATP1B1. No other SNPs that could result in missense mutations were identified. In this study, the association between the four haplotypes constructed with the 388A>G and 521T>C SNPs and DILI risk were evaluated. The allele frequencies of 388A>G were not significantly different between the three groups, while the allele frequencies of 521T>C were significantly different when the CS/mixed injury and HC injury groups were compared to the non-DILI group. The 521T>C SNP has previously been reported to be associated with altered pharmacokinetics of several drugs, including pravastatin, atorvastatin and repaglinide (21) (22) (23) . The incidence of variations in OATP1B1 is known to be dependent on the racial population. The * 1b haplotype is the predominant haplotype in the Chinese population, which is similar to what is observed in the East Asian and sub-Saharan African populations (24) . The * 5 and * 15 haplotypes (with frequencies of 0.72 and 9.52%, respectively), which confer decreased OATP1B1 activity, had higher frequencies than those of East Asian populations. Therefore, the impaired OATP1B1 transport activity possibly contributes to the different frequency of RMP-induced liver injury in different populations by the differing frequencies of OATP1B1 variations. Additionally, RMP treatment has been reported to increase serum bile concentrations in patients with the OATP1B1 * 15 haplotype (25) , and the OATP1B1 The susceptibility to DILI is influenced by an inter-play between many factors, including increased age, gender (women), concurrent drugs, co-morbidity, transporters and genetics. To the best of our knowledge, this is the first study regarding the association of transport protein SNPs with the risk of RMP-induced liver injury. Among many transport proteins, OATP1B1 plays a significant role in bile salt uptake in the enterohepatic circulation of bile salts (26) , and is also a key transporter for RMP. Thus, the functional analyses were preferentially focused on the inhibitory effects of RMP on bile acid transport across HEK293 cells expressing different OATP1B1 variants. TCA was selected to be the substrate for OATP1B1, and the four haplotypes displayed a significant reduction in TCA transport activity. Furthermore, the reduction in the presence of RMP by OATP1B1 * 5 and * 15 (both containing the 521C allele) in the HEK293-OATP1B1 models was greater than that resulting from the * 1b haplotype. The results from other studies also suggest that OATP1B1 is inhibited by RMP in vitro. For example, the reported inhibitory effects on OATP1B1-mediated taurocholate uptake in the presence of RMP were from 58 to 100%, and the decrease of affinity in the mutations also showed a significant reduction of RMP uptake (12, 27) . Furthermore, several studies have shown that the higher the concentration of RMP, the higher the associated inhibition. For example, 10 µM RMP inhibited OATP1B1-mediated Sulfobromophthalein (BSP) uptake in vitro by 69%, while 100 µM RMP almost completely abolished BSP uptake (24) . In our study, the higher the concentration of RMP, the greater the reduction of uptake inhibition.
There were also some limitations in our study. For example, some of our investigated patients were coadministered isoniazid and pyrazinamide with RMP, and thus any confounding effects of isoniazid and pyrazinamide could not be fully eliminated in this study. Nonetheless, the present results indicate that OATP1B1 variants may be involved in the pathogenesis of RMP-induced liver injury and provide a new potential risk factor for patients with this disease.
In conclusion, our genetic epidemiological investigation and functional experimental data suggest that the OATP1B1 * 15 haplotype underlies at least some of the phenotypic variations observed in individual susceptibility to RMP-induced liver injury in a Chinese population. Moreover, the * 15 haplotype possibly plays an important role in the mechanism by which OATP1B1 transports its substrate.
